Lawsuit Accuses Ranbaxy of Manipulating Generic Exclusivity

Drug Industry Daily
A A
A Pennsylvania benefits fund filed suit against generic drugmaker Ranbaxy claiming it used its exclusive status to fraudulently block other generics for several drugs, including Nexium (esomeprazole), Diovan (valsartan) and Valcyte (valganciclovir).

To View This Article:

Login

Subscribe To Drug Industry Daily